研究疾病:
|
腰椎间盘突出症
|
研究疾病代码:
|
|
Target disease:
|
Lumbar disc herniation
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
上市后药物
Post-marketing clinical trial
|
研究目的:
|
评价腰痹通胶囊治疗腰椎间盘突出症(血瘀气滞、脉络闭阻证)的临床有效性及安全性
|
Objectives of Study:
|
to evaluate the efficiacy and safety of Yaobitong Capsules for Lumbar Disc Herniation (syndrome of blood stasis and stagnant qi and syndrome of Venation obstruction )-a multicenter, randomized, double-blind, double-blinded clinical study
|
药物成份或治疗方案详述:
|
试验组服用腰痹通胶囊及颈腰康胶囊模拟剂,对照组服用颈腰康胶囊及腰痹通胶囊模拟剂,服用方法均为口服,一次1袋,一日3次,宜饭后服用。疗程为30天。除试验用药外,试验期间禁止使用其它治疗本病的中西药物或止痛药;试验期间若患者出现不能耐受的疼痛时,可服用美洛昔康片,每天7.5mg或15mg,并在“合并用药表”中详细记录,服用美洛昔康片的受试者,可以继续参加试验,不作无效病例剔除;合并疾病所必须继续服用的药物,或其它治疗,必须在病例报告表中记录药名、用量、使用次数和时间等,以便总结时加以分析和报告。
|
Description for medicine or protocol of treatment in detail:
|
The experimental group took both Yaobitong capsules and Jingyaokang capsules,and Jingyaokang capsules is a simulation agent.The control group took Jingyaokang capsules and Yaobitong capsules, both group were applied oral, 1 bag at a time, 3 times a day, which lasted for 30 days. It was advisable to take it after meals. In addition to the experimental drugs, the use of other Chinese and Western drugs or analgesics for the treatment of the disease is prohibited during the trial.If the patient has intolerable pain during the trial, meloxicam tablets can be taken, 7.5 mg or 15 mg per day, and recorded in detail in the "combined medication table", subjects taking meloxicam tablets can continue to participate in the trial and do not eliminate invalid cases.Drugs that must be continued to be taken for the combined disease, or other treatments, must record the name, dosage, number of uses and time of use in the case report form, etc. So that the summary can be analyzed and reported.
|
纳入标准:
|
(1)符合本病西医诊断标准;
(2)符合本病中医辨证标准;
(3)年龄18~60岁,男性或女性;
(4)30%≤腰椎功能活动障碍指数(ODI)评分≤80%的患者;
(5)30mm≤腰腿疼痛评分≤80mm的患者;
(6)就诊时1周内未用NSAIDs类消炎镇痛药及其他治疗本病的药物;
(7)知情同意,并签署知情同意书。
|
Inclusion criteria
|
(1) Meet the diagnostic criteria of Western medicine;
(2) Meet the TCM syndrome differentiation standard of this disease;
(3) Age range from 18 to 60 years, male or female;
(4) 30% ≤ patients with lumbar functional activity index (ODI) score ≤ 80%;
(5)30mm ≤ Patients with lower back and leg pain score ≤ 80mm;
(6) NSAIDs anti-inflammatory and analgesic drugs and other drugs for the treatment of the disease were not used within 1 week;
(7) Informed consent and sign the informed consent form.
|
排除标准:
|
(1)妊娠或哺乳期妇女;
(2)过敏体质者或对本药过敏者;
(3)手术后复发性腰椎间盘突出症;
(4)无症状腰椎间盘突出,非椎间盘源性腰腿痛;
(5)腰椎间盘突出症合并马尾神经综合征、脊髓圆锥综合征;
(6)腰椎间盘突出症合并腰椎肿瘤或结核、Ⅱ0以上腰椎滑脱、腰椎管狭窄症、强直性脊柱炎、严重骨质疏松症;
(7)腰椎间盘突出症合并严重高血压病、心脏病及其他器官或系统严重原发性疾患,精神病患者;
(8)由于偏头痛、骨关节痛等全身其他部位的急慢性疼痛而影响患者对疼痛的描述者;
(9)近期接受过硬膜外封闭、各种介入治疗和手术治疗者;
(10)已知对美洛昔康片过敏者;
(11)合并有心肝肾(ALT、AST≥正常上限,Cr>正常上限)、造血系统和内分泌系统等严重原发性疾病、精神病、癫痫患者;
(12)三个月内参加过其他临床试验的患者;
(13)研究者认为不宜入选本试验者。
|
Exclusion criteria:
|
(1) women who are pregnant or lactating
(2) patients with allergic constitution or is allergic to this drug
(3) patients with recurrent lumbar disc herniation after operation
(4) patients with asymptomatic lumbar disc herniation or non discogenic low back pain
(5) patients with lumbar disc herniation combined with cauda equina syndrome and conus medullaris syndrome
(6) patients with lumbar disc herniation with lumbar tumor or tuberculosis, spondylolisthesis above Ⅱ 0, lumbar spinal stenosis, ankylosing spondylitis and severe osteoporosis;
(7) patients with lumbar disc herniation complicated with severe hypertension, heart disease and serious primary diseases of other organs or systems, mental patients;
(8) patients whose description of pain were affected due to acute and chronic pain in other parts of the body, such as migraine and bone and joint pain;
(9) patients who have recently received epidural closure, various interventional therapy and surgical treatment;
(10) patients who are allergy to meloxicam tablets;
(11) patients with serious primary diseases such as heart, liver and kidney (alt, AST ≥ upper limit of normal, Cr > upper limit of normal), hematopoietic system and endocrine system, psychosis and epilepsy;
(12) patients who have participated in other clinical trials within three months;
(13) researchers who are not suitable to be selected for this experiment.
|
研究实施时间:
Study execute time:
|
从From
2014-09-01
至To
2016-08-01
|
征募观察对象时间:
Recruiting time:
|
从From
2015-06-15
至To
2016-02-25
|